one-sided / two-sided [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2019-03-04 09:04 (730 d 00:51 ago) – Posting: # 19997
Views: 3,183

Hi Hötzi,


» In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.

There is no more than a 5% risk of approving the test product (=concluding superiority) if the test product is not superior.

» If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.

The patient's risk would be halved (max 2.5% chance of approving a non-BE product; CIs would get wider).

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,360 posts in 4,461 threads, 1,492 registered users;
online 5 (1 registered, 4 guests [including 2 identified bots]).
Forum time: Wednesday 09:55 CET (Europe/Vienna)

The art and science of asking questions
is the source of all knowledge.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5